Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review
Death or dependency · people with acute stroke
Chlormethiazole showed no clear difference in death or dependency compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with acute stroke
Chlormethiazole probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Functional independence · people with acute stroke
Chlormethiazole showed no clear difference in functional independence compared with placebo (moderate certainty).
1 finding from 1 review
Other stroke scales · people with acute stroke
1 finding from 1 review
Death or dependency · people with acute stroke
Diazepam showed no clear difference in death or dependency compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with acute stroke
Diazepam showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Functional independence · people with acute stroke
Diazepam showed no clear difference in functional independence compared with placebo (moderate certainty).
1 finding from 1 review
Other stroke scales · people with acute stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Structural outcome ‐ retinal detachment · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes structural outcome ‐ retinal detachment compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Outcomes* · preterm infants with type 1 ROP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Structural outcome ‐ retinal detachment · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower structural outcome ‐ retinal detachment (unit of analysis: eyes) compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy combined with… changes local adverse effects ‐ perioperative retinal haemorrhages (unit of… compared with laser/cryotherapy (very low certainty).
1 finding from 1 review